Streetbeat News

VVOS

Vivos Therapeutics, Inc.

Industry

Medical - Devices

Vivos Therapeutics, Inc., a medical technology company, develops and commercializes treatment alternatives for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers the Vivos System, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring. Vivos Therapeutics also offers VivoScore Program, a screening and home sleep test in adults and children. The company markets and sells its Vivos System to licensed professionals, primarily general dentists in the United States and Canada. Vivos Therapeutics, Inc. was founded in 2016 and is based in Highlands Ranch, Colorado.

Open

3.25

Mkt cap

19M

Volume

50K

High

3.33

P/E Ratio

-0.66

52-wk high

6.28

Low

3.10

Div yield

N/A

52-wk low

1.91

U.S. stocks traded higher with the Dow Jones gaining over 50 points. The ADP reported that private businesses in the U.S. added 89,000 workers in September, the least since Jan. 2021, and below market estimates of 153,000. Shares of Conduit Pharmaceuticals, Gaucho Group Holdings, and Vivos Therapeutics rose significantly, while shares of Kineta, A10 Networks, and Molekule Group fell. Molekule Group and its subsidiary have filed for Chapter 11 bankruptcy.

Portfolio Pulse from Lisa Levin

October 04, 2023 | 1:44 pm

In Wednesday's pre-market session, several healthcare stocks saw significant movement. Freeline Therapeutics, Vivos Therapeutics, Brainstorm Cell, Sonendo, Senti Biosciences, and Synlogic saw increases in their stock prices, while Kineta, Femasys, Alpha Teknova, Catheter Precision, Standard BioTools, and Addex Therapeutics experienced decreases.

Portfolio Pulse from Benzinga Insights

October 04, 2023 | 1:06 pm

Vivos Therapeutics has entered into strategic agreements with Ormco and On Demand Orthodontist to supply Spark Clear Aligners to its national network of providers. This has led to an increase in Vivos' share price.

Portfolio Pulse from Benzinga Newsdesk

October 04, 2023 | 1:01 pm

Vivos Therapeutics has signed agreements with Ormco and On Demand Orthodontist to supply Spark Clear Aligners to its national network of providers. This is expected to expand Vivos' product line and create additional revenue opportunities in the near term.

Portfolio Pulse from Benzinga Newsdesk

October 04, 2023 | 11:44 am

During Friday's session, 112 companies set new 52-week lows. The largest company by market cap to set a new 52-week low was Hershey (HSY), while the smallest was Ascent Solar Technologies (ASTI). TOP Ships (TOPS) saw the most significant drop, with its stock falling 1028.56% to reach a new 52-week low. Quest Diagnostics (DGX) shares were the most resilient, rising 0.0% from its new 52-week low.

Portfolio Pulse from Benzinga Insights

September 29, 2023 | 6:09 pm

During Thursday's intraday session, several healthcare stocks experienced significant movements. Gainers included MSP Recovery (LIFW), ARS Pharmaceuticals (SPRY), Butterfly Network (BFLY), Ainos (AIMD), Evaxion Biotech (EVAX), and Calliditas Therapeutics (CALT). Losers included Travere Therapeutics (TVTX), Seelos Therapeutics (SEEL), Avinger (AVGR), Meihua Intl Medical Techs (MHUA), Vigil Neuroscience (VIGL), and Vivos Therapeutics (VVOS).

Portfolio Pulse from Benzinga Insights

September 21, 2023 | 5:31 pm

Several healthcare stocks experienced significant price movements during Monday's intraday session. Gainers included Timber Pharmaceuticals (TMBR), China SXT Pharmaceuticals (SXTC), Novo Integrated Sciences (NVOS), China Pharma Holding (CPHI), Fortress Biotech (FBIOP), and Orchestra BioMed Hldgs (OBIO). Losers included CNS Pharma (CNSP), Arcutis Biotherapeutics (ARQT), Modular Medical (MODD), Frequency Therapeutics (FREQ), Vivos Therapeutics (VVOS), and Aziyo Biologics (AZYO).

Portfolio Pulse from Benzinga Insights

August 21, 2023 | 5:31 pm

Healthcare stocks showed significant movement in Wednesday's after-market session. Gainers included Modular Medical (MODD), Atreca (BCEL), Pieris Pharmaceuticals (PIRS), DarioHealth (DRIO), PAVmed (PAVM), and AIM ImmunoTech (AIM). Losers included Vivos Therapeutics (VVOS), Alpha Tau Medical (DRTS), Bio-Path Hldgs (BPTH), Novo Integrated Sciences (NVOS), Alaunos Therapeutics (TCRT), and MSP Recovery (LIFW).

Portfolio Pulse from Benzinga Insights

August 16, 2023 | 9:32 pm

Vivos Therapeutics reported Q2 losses of $(0.18) per share, missing the analyst consensus estimate of $(0.14) by 28.57%. The company also reported quarterly sales of $3.40 million, missing the analyst consensus estimate of $4.15 million by 18.19%. This represents a 45.45% increase in losses and an 18.86% decrease in sales compared to the same period last year.

Portfolio Pulse from Benzinga Newsdesk

August 16, 2023 | 8:15 pm

Vivos Therapeutics has rescheduled its Q2 financial results conference call and reported a delay in filing Form 10-Q. Further details will be provided in a subsequent announcement.

Portfolio Pulse from Benzinga Newsdesk

August 14, 2023 | 9:09 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.